CIK 0001815442 · Large accelerated filer
Kymera Therapeutics, Inc.
Sign in to watch- Ticker
- KYMR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 812992166
- Phone
- 857-285-5314
- Business address
- 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
- Former names
- Kymera Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,158,214
- in 2 filings, $3.4M under 10b5-1 plans
Net −$4,158,214. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-10-13 | Gollob Jared Chief Medical Officer | Option exercise 10b5-1 | +673 | $2.08 | $1K | 121,473 |
| 2025-10-13 | Gollob Jared Chief Medical Officer | Sale 10b5-1 | −3,114 | $60.00 | $187K | 118,359 |
| 2025-10-13 | Gollob Jared Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −800 | 28,999 | ||
| 2025-10-13 | Gollob Jared Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −673 | 22,210 | ||
| 2025-10-13 | Albers Jeffrey W. Director | Option exercise 10b5-1 | +5,000 | $10.34 | $52K | 5,000 |
| 2025-10-13 | Albers Jeffrey W. Director | Sale 10b5-1 | −5,000 | $59.19 | $296K | 0 |
| 2025-10-13 | Albers Jeffrey W. Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,000 | 0 | ||
| 2025-09-17 | Jacobs Bruce N. Chief Financial Officer | Option exercise 10b5-1 | +79,220 | $2.08 | $165K | 306,629 |
| 2025-09-17 | Jacobs Bruce N. Chief Financial Officer | Sale 10b5-1 | −79,220 | $50.00 | $4.0M | 227,409 |
| 2025-09-17 | Jacobs Bruce N. Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −42,246 | 27,653 | ||
| 2025-09-17 | Jacobs Bruce N. Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −36,974 | 0 | ||
| 2025-09-16 | Mainolfi Nello Chief Executive Officer | Option exercise 10b5-1 | +30,000 | $2.08 | $62K | 690,482 |
| 2025-09-16 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 | −30,000 | $49.00 | $1.5M | 660,482 |
| 2025-09-16 | Mainolfi Nello Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −30,000 | 435,559 | ||
| 2025-09-03 | Adams Brian Chief Legal Officer | Grant or award | +52,500 | 52,500 | ||
| 2025-09-03 | Adams Brian Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +105,000 | 105,000 | ||
| 2025-06-30 | BVF PARTNERS L P/IL Director | Purchase | +142,604 | $44.00 | $6.3M | 2,798,795 |
| 2025-06-30 | BVF PARTNERS L P/IL Director | Purchase | +115,783 | $44.00 | $5.1M | 2,219,858 |
| 2025-06-30 | BVF PARTNERS L P/IL Director | Purchase | +58,780 | $44.00 | $2.6M | 353,412 |
| 2025-06-30 | BAKER BROS. ADVISORS LP Director | Purchase | +55,191 | $44.00 | $2.4M | 534,134 |
Page 21 of 25 · 493 trades